Valiant Laboratories Ltd.

•

valiantorganics.comBSE: 543998NSE: VALIANTLAB

Market Cap₹ 692 Cr.

Current Price

High / Low₹ 130 / 50

Stock P/E43.3

Book Value₹ 61

Price to Book1.42

Dividend Yield0.00 %

ROCE-0.4 %

ROE-0.9 %

Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Latest quarter profit grew 1058.9% YoY, showing strong momentum
Strong cash generation - operating cash flow backs reported profits (CFO/PAT 2.18x)

CONS

Company is loss-making at the operating / net level
Receivables are growing faster than sales - a possible quality concern
Interest coverage is weak at -7.6x - earnings barely cover interest
Company has a low return on capital employed of 7.8%
Company has a low return on equity of 9.4% over last 3 years

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY 50 NIFTY 500 NIFTY LARGEMIDCAP 250 NIFTY 100 NIFTY 200

S.No.	Name
1.	SUNPHARMA	1842.00	36.54	441957.50	0.87	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9326.00	84.64	247576.00	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4975.00	86.76	189233.01	0.76	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1119.50	24.74	111670.55	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1365.00	32.72	110272.68	0.95	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1970.35	97.37	106460.42	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	DRREDDY	1161.00	30.07	96906.38	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
8.	AUROPHARMA	1675.45	25.97	96401.69	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
9.	LUPIN	2096.00	17.34	95842.92	0.86	1416.98	16.01	8276.89	34.28	28.86	29.59
10.	MANKIND	2277.00	46.04	94050.37	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2416.90	37.94	68210.88	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	VALIANTLAB	127.48	43.26	692.38	0.00	21.10	1058.87	115.28	146.23	-0.40	25.38

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	51	60	41	31	19	21	35	58	47	46	52	92	115
	48	61	47	35	21	28	35	54	44	46	53	87	90
Operating Profit	4	-1	-6	-5	-2	-7	1	4	2	0	-1	5	25
OPM %	7.43%	-2.32%	-15.55%	-14.81%	-12.66%	-31.38%	1.76%	6.63%	5.13%	0.17%	-1.70%	5.23%	21.97%
	2	3	2	2	3	3	2	-2	1	1	1	0	1
Interest	0	0	0	0	0	0	0	0	0	0	1	1	1
Depreciation	0	0	0	1	1	1	1	1	1	1	2	3	3
Profit before Tax	6	1	-5	-3	-0	-4	2	1	2	0	-3	1	26
Tax %	26.12%	25.47%	30.50%	51.75%	-218.75%	-21.23%	-45.06%	25.53%	25.71%	28.57%	-136.12%	-67.62%	19.43%
Net Profit	0	0	0	0	-1	-5	2	1	2	0	-7	2	21
	1.31	0.24	-0.81	-0.33	-0.12	-1.09	0.54	0.16	0.42	0.04	-1.30	0.32	3.89

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Mar 2024	Mar 2025	TTM
	334	182	133	306
	299	190	138	277
Operating Profit	35	-8	-5	29
OPM %	10.50%	-4.62%	-3.52%	9.59%
	5	10	5	3
Interest	0	0	0	3
Depreciation	2	2	2	8
Profit before Tax	38	-1	-2	25
Tax %	23.96%	141.53%	-45.52%	34.77%
Net Profit	29	0	-2	16
EPS	8.91	0.07	-0.51	—
Dividend Payout %	0.00%	0.00%	0.00%	—

COMPOUNDED SALES GROWTH

10 Years:: —
5 Years:: —
3 Years:: —

COMPOUNDED PROFIT GROWTH

10 Years:: —
5 Years:: —
3 Years:: —

STOCK PRICE CAGR

10 Years:: —
5 Years:: —
3 Years:: —
1 Year:: 49%

RETURN ON EQUITY

10 Years:: —
5 Years:: —
3 Years:: 9%
Last Year:: -1%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Mar 2024	Mar 2025
Equity Capital	33	43	43
	68	193	191
	61	77	122
Trade Payables	47	26	41
	4	2	3
Total Liabilities	213	343	401
	48	50	48
Capital Work in Progress	1	43	156
	34	38	0
	13	10	4
	0	46	72
Cash & Bank	1	106	76
	116	50	45
Total Assets	213	343	401

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Mar 2024	Mar 2025
	65	2	1
Cash from Investing	-55	-144	-53
Cash from Financing	-1	152	45
	-0	10	-7

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Mar 2024	Mar 2025

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	74.94	74.94	74.94	74.94	74.94	74.94	74.94	74.94	74.94
	1.89	0.00	0.00	0.64	0.63	0.02	0.01	0.20	0.00
DIIs	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	23.17	25.06	25.06	24.42	24.43	25.04	25.05	24.86	25.06

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-04

Copy of Newspaper Publication

2026-09-04 - Valiant Laboratories Limited has informed the Exchange regarding Dispatch of Annual Report for FY 2025-26 and Notice of 5th Annual General Meeting to the members of the Company.

2026-09-03

Credit Rating

2026-09-03 - Valiant Laboratories Limited has informed the Exchange about Credit Rating

2026-09-03

General Updates

2026-09-03 - Valiant Laboratories Limited has informed the Exchange 'Letter to shareholders under Regulation 36(1)(b) of SEBI (LODR) Regulations 2015'.

2026-09-03

Shareholders meeting

2026-09-03 - Valiant Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 28, 2026 and the Annual Report for the FY 2025-26

2026-08-31

Copy of Newspaper Publication

2026-08-31 - Valiant Laboratories Limited has informed the Exchange about Copy of Newspaper Publication w.r.t. 5th AGM of the Company

2026-08-12

Copy of Newspaper Publication

2026-08-12 - Valiant Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-10

Monitoring Agency Report

2026-08-10 - Monitoring Agency Report for quarter ended June 30, 2026

2026-08-10

Address Change

2026-08-10 - Valiant Laboratories Limited has informed the Exchange regarding change in Corporate Office of the company.

2026-08-10

Address Change

2026-08-10 - Valiant Laboratories Limited has informed the Exchange regarding change in Registered Office of the company.

News

Recent coverage and analyst commentary for VALIANTLAB

Loading news…

🤖

AI Stock Analyst

Valiant Laboratories Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account

Name

SUNPHARMA

1842.00

36.54

441957.50

0.87

2901.23

26.53

15299.88

10.98

19.11

28.81

DIVISLAB

9326.00

84.64

247576.00

0.32

902.00

65.50

3080.00

27.80

21.51

40.75

TORNTPHARM

4975.00

86.76

189233.01

0.76

566.00

3.28

4921.00

57.32

19.27

33.81

ZYDUSLIFE

1119.50

24.74

111670.55

0.09

990.20

-34.90

8017.00

23.97

21.39

24.54

CIPLA

1365.00

32.72

110272.68

0.95

785.55

-39.18

7119.28

4.13

16.00

16.73

LAURUSLABS

1970.35

97.37

106460.42

0.10

362.07

123.94

2026.31

29.10

18.20

31.50

DRREDDY

1161.00

30.07

96906.38

0.69

435.60

-69.10

8099.80

-5.21

13.75

10.63

AUROPHARMA

1675.45

25.97

96401.69

0.24

1032.03

25.22

9150.35

17.44

12.76

20.54

LUPIN

2096.00

17.34

95842.92

0.86

1416.98

16.01

8276.89

34.28

28.86

29.59

MANKIND

2277.00

46.04

94050.37

0.04

574.09

29.12

4030.59

12.89

13.24

26.30

GLENMARK

2416.90

37.94

68210.88

0.10

482.83

927.88

4018.48

31.35

20.35

20.03

VALIANTLAB

127.48

43.26

692.38

0.00

21.10

1058.87

115.28

146.23

-0.40

25.38

Jun 2023

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

115

Operating Profit

-1

-6

-5

-2

-7

-1

OPM %

7.43%

-2.32%

-15.55%

-14.81%

-12.66%

-31.38%

1.76%

6.63%

5.13%

0.17%

-1.70%

5.23%

21.97%

-2

Interest

Depreciation

Profit before Tax

-5

-3

-0

-4

-3

Tax %

26.12%

25.47%

30.50%

51.75%

-218.75%

-21.23%

-45.06%

25.53%

25.71%

28.57%

-136.12%

-67.62%

19.43%

Net Profit

-1

-5

-7

1.31

0.24

-0.81

-0.33

-0.12

-1.09

0.54

0.16

0.42

0.04

-1.30

0.32

3.89

Mar 2023

Mar 2024

Mar 2025

TTM

334

182

133

306

299

190

138

277

Operating Profit

-8

-5

OPM %

10.50%

-4.62%

-3.52%

9.59%

Interest

Depreciation

Profit before Tax

-1

-2

Tax %

23.96%

141.53%

-45.52%

34.77%

Net Profit

-2

EPS

8.91

0.07

-0.51

—

Dividend Payout %

0.00%

—

Mar 2023

Mar 2024

Mar 2025

Equity Capital

193

191

122

Trade Payables

Total Liabilities

213

343

401

Capital Work in Progress

156

Cash & Bank

106

116

Total Assets

213

343

401

Mar 2023

Mar 2024

Mar 2025

Cash from Investing

-55

-144

-53

Cash from Financing

-1

152

-0

-7

Mar 2023

Mar 2024

Mar 2025

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

74.94

1.89

0.00

0.64

0.63

0.02

0.01

0.20

0.00

DIIs

0.00

Government

0.00

23.17

25.06

24.42

24.43

25.04

25.05

24.86

25.06

Valiant Laboratories Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI

Valiant Laboratories Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI